Bone mineral density as a marker of cumulative endogenous estrogen exposure: Relationship to background genetic risk of psychotic disorder

Schizophrenia Research

Volumn 143, Issue 1, 2013, Pages 25-31

  van der Leeuw, C ^a   Habets, P ^a   Domen, P ^a   van Kroonenburgh, M ^a   van Os, J ^a,b   Marcelis, M ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Bone mineral density; Endophenotype; Estrogen; Genetics; Psychotic disorder; Schizophrenia

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; BENZODIAZEPINE DERIVATIVE; CHOLINERGIC RECEPTOR BLOCKING AGENT; ESTROGEN; HALOPERIDOL; METHYLPHENIDATE; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT; RISPERIDONE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; ZUCLOPENTHIXOL;

ADOLESCENT; ADULT; ANALYTICAL PARAMETERS; ARTICLE; BONE DENSITY; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; DYSMENORRHEA; ENDOPHENOTYPE; ESTROGEN BLOOD LEVEL; FEMALE; FEMUR; GENETIC ASSOCIATION; GENETIC RISK; HUMAN; LONGITUDINAL STUDY; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; MENARCHE; NETHERLANDS; OSTEOPENIA; OSTEOPOROSIS; OUTCOME ASSESSMENT; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PSYCHOSIS; SEX DIFFERENCE; SIBLING; SUN EXPOSURE; T SCORE; Z SCORE;

ABSORPTIOMETRY, PHOTON; ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BONE DENSITY; BONE DISEASES, METABOLIC; ESTROGENS; FEMALE; HUMANS; MALE; MIDDLE AGED; MOTOR ACTIVITY; OSTEOPOROSIS; PSYCHOTIC DISORDERS; SEX FACTORS; SPINAL CORD; SUNLIGHT; YOUNG ADULT;

EID: 84871930990     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2012.10.031     Document Type: Article

References (40)

1. Abraham G., Halbreich U., Friedman R.H., Josiassen R.C. Bone mineral density and prolactin associations in patients with chronic schizophrenia. Schizophr. Res. 2003, 59(1):17-18.
2. Abraham G., Paing W.W., Kaminski J., Joseph A., Kohegyi E., Josiassen R.C. Effects of elevated serum prolactin on bone mineral density and bone metabolism in female patients with schizophrenia: a prospective study. Am. J. Psychiatry 2003, 160(9):1618-1620.
3. Andreasen N.C., Flaum M., Arndt S. The Comprehensive Assessment of Symptoms and History (CASH). An instrument for assessing diagnosis and psychopathology. Arch. Gen. Psychiatry 1992, 49(8):615-623.
4. APA Diagnostic and Statistical Manual of Mental Disorders 2000, American Psychiatric Association, Washington, D.C. 4th edition.
5. Azcoitia I., Arevalo M.A., De Nicola A.F., Garcia-Segura L.M. Neuroprotective actions of estradiol revisited. Trends Endocrinol. Metab. 2011, 22(12):467-473.
6. Bab I., Zimmer A., Melamed E. Cannabinoids and the skeleton: from marijuana to reversal of bone loss. Ann. Med. 2009, 41(8):560-567.
7. Bergemann N., Parzer P., Mundt C., Auler B. High bone turnover but normal bone mineral density in women suffering from schizophrenia. Psychol. Med. 2008, 38(8):1195-1201.
8. Bilici M., Cakirbay H., Guler M., Tosun M., Ulgen M., Tan U. Classical and atypical neuroleptics, and bone mineral density, in patients with schizophrenia. Int. J. Neurosci. 2002, 112(7):817-828.
9. Boerma M.A., van der Stel J.C., van Amelsvoort T., Linszen D.H., de Haan L. Women, schizophrenia and oestrogen; neurobiological hypotheses and hormonetherapy studies. Tijdschr. Psychiatr. 2010, 52(4):235-244.
10. Clayton D., Hills M. Statistical Models in Epidemiology 1993, Oxford University Press, Oxford.
11. Clemons M., Goss P. Estrogen and the risk of breast cancer. N. Engl. J. Med. 2001, 344(4):276-285.
12. Delva N.J., Crammer J.L., Jarzylo S.V., Lawson J.S., Owen J.A., Sribney M., Weir B.J., Yendt E.R. Osteopenia, pathological fractures, and increased urinary calcium excretion in schizophrenic patients with polydipsia. Biol. Psychiatry 1989, 26(8):781-793.
13. Goldstein H. Multilevel Models in Educational and Social Research 1987, Griffin, London.
14. Habets P., Marcelis M., Gronenschild E., Drukker M., van Os J. Reduced cortical thickness as an outcome of differential sensitivity to environmental risks in schizophrenia. Biol. Psychiatry 2011, 69(5):487-494.
15. Haddad P.M., Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 2004, 64(20):2291-2314.
16. Halbreich U. Osteoporosis, schizophrenia and antipsychotics: the need for a comprehensive multifactorial evaluation. CNS Drugs 2007, 21(8):641-657.
17. Howard L., Kirkwood G., Leese M. Risk of hip fracture in patients with a history of schizophrenia. Br. J. Psychiatry 2007, 190:129-134.
18. Howes O.D., Wheeler M.J., Meaney A.M., O'Keane V., Fogelman I., Blake G., Murray R.M., Smith S. Bone mineral density and its relationship to prolactin levels in patients taking antipsychotic treatment. J. Clin. Psychopharmacol. 2005, 25(3):259-261.
19. Hummer M., Malik P., Gasser R.W., Hofer A., Kemmler G., Moncayo Naveda R.C., Rettenbacher M.A., Fleischhacker W.W. Osteoporosis in patients with schizophrenia. Am. J. Psychiatry 2005, 162(1):162-167.
20. Kinon B.J., Gilmore J.A., Liu H., Halbreich U.M. Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology 2003, 28(Suppl. 2):55-68.
21. Kishimoto T., Watanabe K., Shimada N., Makita K., Yagi G., Kashima H. Antipsychotic-induced hyperprolactinemia inhibits the hypothalamo-pituitary-gonadal axis and reduces bone mineral density in male patients with schizophrenia. J. Clin. Psychiatry 2008, 69(3):385-391.
22. Kolsch H., Rao M.L. Neuroprotective effects of estradiol-17beta: implications for psychiatric disorders. Arch. Womens Ment. Health 2002, 5(3):105-110.
23. Korver N., Quee P.J., Boos H.B., Simons C.J., de Haan L. Genetic Risk and Outcome of Psychosis (GROUP), a multi site longitudinal cohort study focused on gene-environment interaction: objectives, sample characteristics, recruitment and assessment methods. Int. J. Methods Psychiatr. Res. 2012, 21(3):205-221.
24. Kulkarni J., de Castella A., Fitzgerald P.B., Gurvich C.T., Bailey M., Bartholomeusz C., Burger H. Estrogen in severe mental illness: a potential new treatment approach. Arch. Gen. Psychiatry 2008, 65(8):955-960.
25. Kulkarni J., Gurvich C., Lee S.J., Gilbert H., Gavrilidis E., de Castella A., Berk M., Dodd S., Fitzgerald P.B., Davis S.R. Piloting the effective therapeutic dose of adjunctive selective estrogen receptor modulator treatment in postmenopausal women with schizophrenia. Psychoneuroendocrinology 2010, 35(8):1142-1147.
26. Kulkarni J., de Castella A., Headey B., Marston N., Sinclair K., Lee S., Gurvich C., Fitzgerald P.B., Burger H. Estrogens and men with schizophrenia: is there a case for adjunctive therapy?. Schizophr. Res. 2011, 125(2-3):278-283.
27. Lee T.Y., Chung M.Y., Chung H.K., Choi J.H., Kim T.Y., So H.S. Bone density in chronic schizophrenia with long-term antipsychotic treatment: preliminary study. Psychiatry Investig. 2010, 7(4):278-284.
28. Lehman D., Meyer J.M. Decreased bone mineral density in male schizophrenia patients. Schizophr. Res. 2005, 76(1):131-133.
29. Maric N., Popovic V., Jasovic-Gasic M., Pilipovic N., van Os J. Cumulative exposure to estrogen and psychosis: a peak bone mass, case-control study in first-episode psychosis. Schizophr. Res. 2005, 73(2-3):351-355.
30. Maurel D.B., Boisseau N., Benhamou C.L., Jaffre C. Alcohol and bone: review of dose effects and mechanisms. Osteoporos. Int. 2012, 23(1):1-16.
31. Meaney A.M., O'Keane V. Bone mineral density changes over a year in young females with schizophrenia: relationship to medication and endocrine variables. Schizophr. Res. 2007, 93(1-3):136-143.
32. Meaney A.M., Smith S., Howes O.D., O'Brien M., Murray R.M., O'Keane V. Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia. Br. J. Psychiatry 2004, 184:503-508.
33. Melcangi R.C., Panzica G., Garcia-Segura L.M. Neuroactive steroids: focus on human brain. Neuroscience 2011, 191:1-5.
34. Meyer J.M., Lehman D. Bone mineral density in male schizophrenia patients: a review. Ann. Clin. Psychiatry 2006, 18(1):43-48.
35. Partti K., Heliovaara M., Impivaara O., Perala J., Saarni S.I., Lonnqvist J., Suvisaari J.M. Skeletal status in psychotic disorders: a population-based study. Psychosom. Med. 2010, 72(9):933-940.
36. Renn J.H., Yang N.P., Chou P. Effects of plasma magnesium and prolactin on quantitative ultrasound measurements of heel bone among schizophrenic patients. BMC Musculoskelet. Disord. 2010, 11:35.
37. Rodland E. Simes' procedure is 'valid on average'. Biometrika 2006, 93(3):742-746.
38. Simes R. An improved Bonferroni procedure for multiple tests of significance. Biometrika 1986, 73:751-754.
39. Smith S.M., O'Keane V., Murray R. Sexual dysfunction in patients taking conventional antipsychotic medication. Br. J. Psychiatry 2002, 181:49-55.
40. WHO Composite International Diagnostic Interview (CIDI) 1990, World Health Organization, Geneva.